These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

637 related articles for article (PubMed ID: 29494592)

  • 1. Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: A cohort study.
    Hwang TJ; Tomasi PA; Bourgeois FT
    PLoS Med; 2018 Mar; 15(3):e1002520. PubMed ID: 29494592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enabling Development of Paediatric Medicines in Europe: 10 Years of the EU Paediatric Regulation.
    Tomasi PA; Egger GF; Pallidis C; Saint-Raymond A
    Paediatr Drugs; 2017 Dec; 19(6):505-513. PubMed ID: 28900869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More medicines for children: impact of the EU paediatric regulation.
    Nordenmalm S; Tomasi P; Pallidis C
    Arch Dis Child; 2018 Jun; 103(6):557-564. PubMed ID: 29490933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2014.
    Deane BR; Porkess S
    Curr Med Res Opin; 2018 Jul; 34(7):1239-1243. PubMed ID: 29219621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trial transparency: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved recently in Europe.
    Rawal B; Deane BR
    Curr Med Res Opin; 2014 Mar; 30(3):395-405. PubMed ID: 24168052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.
    Collignon O; Koenig F; Koch A; Hemmings RJ; Pétavy F; Saint-Raymond A; Papaluca-Amati M; Posch M
    Trials; 2018 Nov; 19(1):642. PubMed ID: 30454061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018.
    Schuster Bruce C; Brhlikova P; Heath J; McGettigan P
    PLoS Med; 2019 Sep; 16(9):e1002873. PubMed ID: 31504034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
    Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X
    Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moving toward a paradigm shift in the regulatory requirements for pediatric medicines.
    Chin WW; Joos A
    Eur J Pediatr; 2016 Dec; 175(12):1881-1891. PubMed ID: 27646479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act.
    Hwang TJ; Orenstein L; Kesselheim AS; Bourgeois FT
    JAMA Pediatr; 2019 Jan; 173(1):68-74. PubMed ID: 30452498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug evaluation in children 10years after the European pediatric regulation current challenges and perspectives.
    Élie V; Leroux S; Kaguelidou F; Jacqz-Aigrain E
    Therapie; 2018 Apr; 73(2):113-117. PubMed ID: 29580612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the EU Paediatric Medicine Regulation on new anti-cancer medicines for the treatment of children and adolescents.
    Vassal G; de Rojas T; Pearson ADJ
    Lancet Child Adolesc Health; 2023 Mar; 7(3):214-222. PubMed ID: 36682367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2013.
    Deane BR; Sivarajah J
    Curr Med Res Opin; 2017 Mar; 33(3):473-478. PubMed ID: 27869482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug development: EU paediatric legislation, the European Medicines Agency and its Paediatric Committee--adolescents' melanoma as a paradigm.
    Rose K; Senn S
    Pharm Stat; 2014; 13(4):211-3. PubMed ID: 24903307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introduction or Discontinuation of Additional Risk Minimisation Measures During the Life Cycle of Medicines in Europe.
    Francisca RDC; Baba E; Hoeve CE; Zomerdijk IM; Sturkenboom MCJM; Straus SMJM
    Drug Saf; 2021 Jan; 44(1):63-72. PubMed ID: 33000427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2012.
    Rawal B; Deane BR
    Curr Med Res Opin; 2015; 31(7):1431-5. PubMed ID: 25942525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three years of paediatric regulation in the European Union.
    Olski TM; Lampus SF; Gherarducci G; Saint Raymond A
    Eur J Clin Pharmacol; 2011 Mar; 67(3):245-52. PubMed ID: 21286912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The development of medicines for children. Part of a series on Pediatric Pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni.
    Rocchi F; Tomasi P
    Pharmacol Res; 2011 Sep; 64(3):169-75. PubMed ID: 21376810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.